Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2006
11/21/2006US7138378 Preparing a suppression effector and replacement nucleic acid that have modifications in one or more third base (wobble) positions so that replacement nucleic acids still code for the wild type or equivalent amino acids
11/21/2006US7138272 Gene transfer in human lymphocytes using retroviral scFv cell targeting
11/21/2006US7138234 Gene involved in CADASIL, method of diagnosis and therapeutic application
11/21/2006US7138127 Clostridial toxin derivatives and methods for treating pain
11/21/2006US7138122 Therapeutic systems
11/21/2006US7138112 Plasmid maintenance system for antigen delivery
11/17/2006CA2549902A1 Cd44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
11/16/2006WO2006122242A2 Compositions and methods for the treatment of inflammatory bowel disease utilizing nf-kb decoy polynucleotides
11/16/2006WO2006122060A1 Compositions and uses of secreted polypeptide, zsig98
11/16/2006WO2006121960A2 Methods and sequences to suppress primate huntington gene expression
11/16/2006WO2006121951A2 Antisense antiviral compounds and methods for treating foot and mouth disease
11/16/2006WO2006121871A2 Compositions and methods for modulating cells via cd14 and toll-like receptor 4 signaling pathway
11/16/2006WO2006121810A2 Trimeric ox40-immunoglobulin fusion protein and methods of use
11/16/2006WO2006121532A2 Treatment for heart disease
11/16/2006WO2006120455A2 Ovalbumin promoter constructs for retroviral vectors
11/16/2006WO2006120160A1 Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases
11/16/2006WO2006119965A2 Growth factor mutants with altered biological attributes
11/16/2006WO2006119647A1 Oligonucleotides and methods of use
11/16/2006WO2006088849A3 Metabolic-based methods for modulating gene expression
11/16/2006WO2006073458A8 Oligonucleotides comprising a c5-modified pyrimidine
11/16/2006WO2005081714A3 Use of interfering rna in the production of transgenic animals
11/16/2006WO2005072703A3 Controlled and sustained delivery of nucleic acid-based therapeutic agents
11/16/2006US20060259988 Use of dg931 protein for treating diabetes, obesity and metabolic syndrome
11/16/2006US20060258611 Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
11/16/2006US20060258610 Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
11/16/2006US20060258609 Method for inhibition of lipogenesis by regulating PRP19 expression
11/16/2006US20060258608 RNAi modulation of RSV and therapeutic uses thereof
11/16/2006US20060258607 Ghrelin binding nucleic acids
11/16/2006US20060258606 Transforming growth factor-beta response element decoys and methods
11/16/2006US20060258605 Nucleolin-mediated cancer diagnostics and therapy
11/16/2006US20060258604 Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
11/16/2006US20060258603 Transposon-based targeting system
11/16/2006US20060258602 Site-specific gene conversion promoter and gene therapeutic
11/16/2006US20060258601 Formulation for inwardly transferring nucleic acids into eucaryotic cells
11/16/2006US20060258567 Xcrf polynucleotides and polypeptides and uses thereof
11/16/2006US20060258005 Novel virus vector
11/16/2006US20060258003 Culture medium composition, culture method, and myoblasts obtained, and their uses
11/16/2006US20060257965 Extracellular matrix signalling molecules
11/16/2006US20060257928 ANGE gene in atopy
11/16/2006US20060257912 Methods and sequences to suppress primate huntington gene expression
11/16/2006US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006US20060257872 Cell lines and host nucleic acid sequences related to infectious disease
11/16/2006US20060257867 Ghrelin binding nucleic acids
11/16/2006US20060257465 Methods for preparation of lipid-encapsulated therapeutic agents
11/16/2006US20060257431 Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
11/16/2006US20060257411 Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
11/16/2006US20060257409 Breast Specific Genes and Proteins
11/16/2006US20060257405 Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr)
11/16/2006US20060257383 Human skin equivalents expressing exogenous polypeptides
11/16/2006US20060257382 Corneal cells expressing active agents and methods of use thereof
11/16/2006US20060257381 Method for transplanting lymphohematopoietic cells into mammal
11/16/2006US20060257380 Use of sirnas for gene silencing in antigen presenting cells
11/16/2006US20060257371 Adenoviral vectors for treating diseases
11/16/2006US20060257370 Adenoviral vectors for treating diseases
11/16/2006US20060257369 Therapeutic regimen for treating cancer
11/16/2006US20060257368 Devices and methods for improved viability of cells
11/16/2006US20060257367 Tumour-cell specific gene expression and its use in cancer therapy
11/16/2006US20060257366 Chimeric glycoproteins and pseudotyped lentiviral vectors
11/16/2006DE102005022290A1 Composition, useful to treat or prevent viral infection, comprises a hexanucleotide as biological component and optionally a carrier, where the hexanucleotide arranged in specific direction against a protein-like biopolymer
11/16/2006CA2651376A1 Method for diagnosis and treatment of a mental disease
11/16/2006CA2607218A1 Use of mapc or progeny therefrom to populate lymphohematopoietic tissues
11/16/2006CA2607044A1 Cardiovascular disease therapies
11/16/2006CA2606778A1 Vascular disease therapies
11/16/2006CA2603857A1 Treatment for heart disease
11/16/2006CA2586250A1 Compositions for treating respiratory viral infections and their use
11/15/2006EP1721987A1 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
11/15/2006EP1721979A1 Compositions and methods for increasing bone mineralisation
11/15/2006EP1721909A1 Growth factor mutants with altered biological attributes
11/15/2006EP1721005A1 Method for detecting the risk of cancer, coronary heart disease, and stroke by analysing a catalase gene
11/15/2006EP1721003A1 Diagnostics and therapeutics for diseases associated with kallikrein 5 (klk5)
11/15/2006EP1720984A1 Methods and compositions for treatment or prevention of secondary ischemic injury
11/15/2006EP1720893A2 Compositions and methods for the systemic treatment of arthritis
11/15/2006EP1720571A2 Method of treating hemolytic disease
11/15/2006EP1720568A2 Immunostimulatory viral rna oligonucleotides
11/15/2006EP1720522A1 Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, dna vaccination and administration of gene based drugs
11/15/2006EP1720519A1 Lyophilization method to improve excipient crystallization
11/15/2006EP1198560B1 Mammalian adhesion protease
11/15/2006EP1064372B1 Compounds and methods for therapy and diagnosis of lung cancer
11/15/2006EP1054950B1 Hiv chemokines
11/15/2006EP1008351B1 Carcinostatic agents
11/15/2006CN1863815A Polypeptides having brain disposition activity and utilization of the same
11/15/2006CN1863559A 化合物 Compound
11/15/2006CN1861195A Fowl vaccine immunopotentiator of chicken interleuken-18, and its application
11/15/2006CN1861194A Anti gastrin-releasing peptide nucleic acid vaccine and its prepn. method
11/15/2006CN1861190A Application of anion exchange protein 1 and gene used as target for preparing medicine to treat alimentary canal tumor
11/15/2006CN1284854C Mosaic type DNA vaccine in use for preventing tuberculosis and immunological therapy
11/15/2006CN1284604C Target directional DNA vaccine for preventing caries and preparation method thereof
11/15/2006CN1284523C Method of coating fine particle with lipid film
11/14/2006US7135549 Can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization
11/14/2006US7135463 inhibiting the growth of a cancerous cell by contacting cell with an effective amount of a RhoB protein, or a variant of the RhoB protein; alone or in combination with additional anti-cancer agents, such as cytotoxic agents (e.g., 5-flurouracil)
11/14/2006US7135339 Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
11/14/2006US7135324 Viral recombinases, related articles, and methods of use thereof
11/14/2006US7135321 Truncated glycogen synthase kinase 3 crystallizable polypeptide; drug screening for Alzheimer's Disease treatments, antidiabetic and antiinflammatory agents
11/14/2006US7135303 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
11/14/2006US7135286 Pharmaceutical and diagnostic business systems and methods
11/14/2006US7135190 Biodegradable and water soluble polyesterether block polymers possessing reverse thermal gelation properties, used for drug delivery of genes, peptides, anticancer or antiproliferative agents
11/14/2006US7135187 System for production of helper dependent adenovirus vectors based on use of endonucleases
11/14/2006US7135181 Method for down-regulation of amyloid
11/14/2006US7135171 Endothelial precursor cells for enhancing and restoring vascular function